Skip to content
AnalystLens

Charles River Laboratories International 8-K Report, Regulation FD Disclosure (Sep 24, 2026)

Reports
Regulation FD·Exhibits & Filings
Filing Date
Filed September 24, 2026
Period End
September 24, 2026
Security
CRL
In the record · 2016–202610-K1110-Q338-K117

CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 117 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Apr ’18Apr ’18
  2. Material agreement8-K · Oct ’19Oct ’19
  3. Leadership change8-K · Jan ’22Jan ’22
  4. Leadership change8-K · Sep ’25Sep ’25

Summary

Summary of the 8-K filed September 24, 2026. Cited figures are marked; the original filing is the authoritative source.

Charles River Laboratories International, Inc. (NYSE: CRL) furnished a press release dated September 24, 2026, issued in connection with its 2026 Investor Day.

The release outlines the company's "Pathway to Purpose" strategy, which rests on three initiatives: modernizing the company to drive productivity and efficiency, strengthening its scientific portfolio, and delivering a customized, client-centric approach. The company expects over $300 milliona in cumulative savings from its Create the Future™ program from 2027 through 2030, and it expects bioanalysis revenue to grow organically at a high-single-digit CAGR to approximately $450 million in 2030. The company reaffirmed its 2026 financial guidance, last updated on August 5, 2026, and now expects revenue and non-GAAP earnings per share at the upper ends of their prior ranges, primarily reflecting continued favorable demand from biopharmaceutical clients.

The 2026 guidance ranges are 0% to 1% organic revenue growth, a non-GAAP operating margin of 21.0% to 21.3%, and non-GAAP EPS of $11.15 to $11.45b. For 2030, the company introduced long-term targets of 5% to 7% organic revenue growth (2027-2030 CAGR), a non-GAAP operating margin of approximately 24%, and low-double-digit non-GAAP EPS growth (2027-2030 CAGR).

The company states these targets do not include future acquisitions or divestitures, are not projections, and are not financial guidance. The information is furnished under Item 7.01 and is not deemed filed for purposes of Section 18 of the Exchange Act.

Key Highlights

  1. Reaffirmed 2026 guidance, now expecting revenue and non-GAAP EPS at the upper ends of prior ranges, driven by continued favorable biopharmaceutical client demand.
  2. Introduced 2030 targets: 5% to 7% organic revenue growth (2027-2030 CAGR), non-GAAP operating margin of approximately 24%, and low-double-digit non-GAAP EPS CAGR (2027-2030).
  3. Create the Future™ program expected to generate over $300 million in cumulative savings from 2027 through 2030 through simplified processes, automation, and digital enablement.
  4. Bioanalysis revenue expected to grow organically at a high-single-digit CAGR to approximately $450 million in 2030, a priority investment area alongside in vitro testing.
  5. Apollo™ cloud-based platform now serves more than 18,000 client users and was recently expanded to support Manufacturing Solutions clients.
  6. 2030 targets exclude the impact of future acquisitions or divestitures and are explicitly not financial guidance.

Frequently Asked Questions

  1. Did Charles River change its 2026 financial outlook at Investor Day?

    The company reaffirmed its 2026 guidance, last updated August 5, 2026, and now expects revenue and non-GAAP earnings per share at the upper ends of their respective ranges. The filing attributes this primarily to continued favorable demand from biopharmaceutical clients.

  2. What are the new long-term financial targets through 2030?

    The company targets organic revenue growth of 5% to 7% (2027-2030 CAGR), a non-GAAP operating margin of approximately 24%, and low-double-digit non-GAAP EPS growth (2027-2030 CAGR). The filing states these are not projections or financial guidance and are subject to significant uncertainties.

  3. What is the Create the Future™ program and what savings does it target?

    Create the Future™ is a recently introduced program through which the company expects to generate over $300 million in cumulative savings from 2027 through 2030. It aims to simplify processes and increase automation and digital enablement, including expanded use of AI-assisted digital tools.

  4. How is Charles River positioning its scientific portfolio?

    The company plans to expand its scientific capabilities through organic and inorganic investments, prioritizing bioanalysis, in vitro testing, and related solutions. It expects bioanalysis revenue to grow organically at a high-single-digit CAGR to approximately $450 million in 2030.